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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of exercise therapy, alone and in combination, for people with chronic fatigue syndrome (CFS) compared with
treatment as usual control conditions and other interventions (psychological therapies, pharmacological treatment).
B A C K G R O U N D
Description of the condition
Chronic fatigue syndrome (CFS) is an illness characterised by
persistent, medically-unexplained fatigue, which is severe enough
to result in substantial disability. Fatigue is usually accompanied
by other symptoms such as musculoskeletal pain, sleep distur-
bance, headaches, and impaired concentration and short-term
memory (Fukuda 1994; Prins 2006; Sharpe 1991). Some authors
believe that myalgic encephalomyelitis (ME) is a separate condi-
tion (Carruthers 2011), while others believe that ME and CFS are
the same (Medical Research Council 2003). However CFS is the
term that has been adopted and clearly defined for research pur-
poses and will be used in this review. The diagnosis requires alter-
native conditions to be excluded. The prevalence of CFS among
adults ranges from 0.2% to 2.6% (Prins 2006; Ranjith 2005) and
this variation might be related to heterogeneity in diagnostic pro-
cedures as there have been at least 20 sets of diagnostic criteria
published since 1988 (Brurberg 2014; Christely 2012).
The etiology and pathophysiology of CFS are controversial. Mod-
els of understanding can be broadly divided into biomedical and
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biopsychosocial models. The biomedicalmodel explains the illness
as caused by abnormalities of the immune, central nervous (Nijs
2011) or endocrine systems and/or a persistent infectious agent.
The multifactorial biopsychosocial model (Moss-Morris 2012)
distinguishes between precipitating and maintaining factors. Pre-
cipitating factors may include acute infective illness and/or exces-
sive stress, while the illness is maintained by the interaction of
behavior, thoughts, emotions and physiology. For example, after
a severe infection or other illness, attempts to get back to normal
life may result in bursts of activity punctuated by the need to rest
up to recover, known as all-or-nothing behaviour (Moss-Morris
2010; Spence 2005). These periodic bursts of activity may exacer-
bate symptoms and result in failure, which further reinforces suf-
ferers’ belief that they have a serious, ongoing illness. As time goes
by, efforts to meet previous standards of achievement are aban-
doned and patients become increasingly inactive and distressed by
their ongoing symptoms. Inactivity in turn leads to physiologi-
cal changes such as cardiovascular and muscular deconditioning,
dysregulation of the hypothalamic-pituitary-adrenal axis and dis-
rupted circadian rhythms. In this deconditioned state, any activity
is liable to produce symptoms, the experience of which reinforces
the fearful beliefs and hence reinforces the avoidance of activity
(fear avoidance).
Description of the intervention
There are no curative treatments for CFS and the primary goals
of treatment are symptom, function and quality of life manage-
ment (NICE 2007). Treatment strategies typically involve exer-
cise therapy and cognitive behavioural therapy (CBT) in addi-
tion to symptom-specific treatments, such as activity pacing and
sleep hygiene. Pharmacotherapy is not an indicated treatment for
CFS other than for symptom management or comorbid condi-
tions such as depression or sleep disruption (BMJ Best Practice
2013).
Exercise is physical activity that requires effort (OED 2012). Ex-
ercise therapy uses physical exercise to improve health and well-
being in people who are unwell, and can include modalities such as
strength training or endurance exercise given as a part of a goal-ori-
ented, multidisciplinary approach (Rietberg 2004; Takken 2008).
There are a number of different approaches to exercise therapy
for CFS. These include aerobic exercise such as walking, jogging,
swimming or cycling, as well as anaerobic exercise such as strength
or stabilising exercises. It is important to look at all kinds of ther-
apeutic exercise, not only aerobic exercise. Behavioral approaches
which use carefully graded exercise as a form of systematic desen-
sitisation focus on breaking the fear avoidance cycle and the ten-
dency to interpret symptoms as signs of illness. These approaches
usually set a low initial exercise level, which gives patients the op-
portunity to experience exercise which does not produce a large
increase in symptoms. Exercise is then built up gradually in a pro-
gramme agreed in advance with the patient. If patients experience
an increase in symptoms, then planned increases in exercise fre-
quency, duration or intensity are temporarily deferred until symp-
toms are less intense. Exercise therapy based on improving fitness
typically involves setting targets based on physiological indicators
of baseline fitness (such as VO2 max) and prescribing increases
in exercise based on ongoing monitoring of measures of fitness.
Whereas both of the above types of exercise therapy include grad-
ual increases in activity over time, a third approach allows patients
to reduce activity in response to symptom exacerbations.
Anaerobic exercise, such as pilates, the Mensendieck system and
Qigong are stabilising exercises with slow movement, primarily
targeting core muscles. Qigong exercise, a method taken from
traditional Chinese medicine, is characterised by a low degree of
intensity and slow movements, coordinated with breathing and a
health-promoting meditative practice. Qigong has been suggested
to improve the postural, stabilising muscular system which often
gradually progresses to more complex movements (Tsang 2003).
Strength training aims to build the strength, anaerobic endurance,
and size of skeletal muscles by resistance training, weight training
or isometric training, but is also an integral part of other exercise
regimes. Strength training exercise is primarily anaerobic.
How the intervention might work
Various models exist to explain why exercise therapy might be a
viable treatment for CFS. The deconditioning model suggests that
CFS is perpetuated by a chronic reduction and avoidance of activ-
ity leading to reversible physiological changes of deconditioning (
Clark 2005; White 2011). In support of the model, CFS patients
show a decreased exercise capacity when compared to sedentary
controls (Fulcher 2000), but to date, improvements in fitness fol-
lowing exercise therapy have not been linked to improvements in
fatigue in people with CFS (Fulcher 2000; Moss-Morris 2005).
The biopsychosocial model emphasises the role of patients’ cog-
nitions and behaviours in the perpetuation of CFS. One vari-
ant of this model suggests exercise therapy reduces the focus on
symptoms and avoidance of feared activity through showing that
gradual increases in activity do not unduly exacerbate symptoms
(Moss-Morris 2005),thereby engendering belief change. Reduc-
tions in beliefs the about harmful effects of exercise have also been
related to improved outcomes in CFS (Deale 1997). A second
variant suggests that graded exposure to the previously-avoided
exercise extinguishes the conditioned response to exercise.
Further research is needed to verify different hypothesis, but ef-
fective treatments may be discovered without knowledge of the
effective pathway or underlying cause.
Why it is important to do this review
Exercise therapy is often used as treatment for CFS both on its
own and as part of a treatment program. The available evidence
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(Edmonds 2004; Larun 2011) strongly suggests that exercise ther-
apymight be effective in the treatment ofCFS.However it has been
reported in one trial that health-related quality of life does not im-
prove with exercise (Nunez 2011) and argued in a review that rest,
pacing and conserving energy are better treatments (Twisk 2009).
People with CFS should have the opportunity to make decisions
about their treatment informed by robust research evidence. This
review will examine the effectiveness of exercise therapy, either
as a stand-alone intervention or as one part of a treatment plan.
Cochrane reviews address many aspects of treatments for CFS. A
review of CBT was published in 2008 (Price 2008), and of tradi-
tional Chinese herbal medicine in 2009 (Adams 2009).
Ameta-analysis of individual participant data (IPD)may be amore
reliable method than using only aggregate data meta-analyses. The
use of IPD facilitates standardisation of analyses and reporting of
results across studies, and allows direct derivation of outcomes,
independent of how these were reported (Riley 2010). IPD also
increases the power to detect differential treatment effects between
the individual participants, providing additional information on
who is most likely to respond.
Analysis based on IPD also enables us to use a wider range of sta-
tistical and analytical approaches (Higgins 2011a). In particular,
it will allow us to explore more thoroughly the relative importance
of the aspects of heterogeneity such as type of exercise, intensity,
incremental procedures, treatment provided to participants in the
control group, baseline illness, and selection criteria, and ensure
that missing data and baseline differences are dealt with in stan-
dardised ways. Access to IPD also allows subgroup analyses that
were not previously reported.
O B J E C T I V E S
To assess the effects of exercise therapy, alone and in combina-
tion, for people with chronic fatigue syndrome (CFS) compared
with treatment as usual control conditions and other interventions
(psychological therapies, pharmacological treatment).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials, including cluster-
randomised trials and cross-over trials, published or unpublished.
While every effort will be made to obtain individual participant
data (IPD) for trials which meet the selection criteria, an eligible
trial will not be excluded if we cannot obtain access to the raw
data.
Types of participants
We will include male and female participants over the age of 17,
irrespective of culture and setting. As several sets of criteria are
currently used to diagnose CFS (Sharpe 1991; Fukuda 1994;
Carruthers 2011) we will include trials given that the patients fulfil
the following diagnostic criteria for CFS:
• Fatigue or a synonym is a prominent symptom;
• Fatigue is medically unexplained (i.e. other diagnosis
known to cause fatigue such as psychiatric disorders and cancer
should be excluded);
• Fatigue is sufficiently severe to significantly disable or
distress the patient; and
• Fatigue has persisted for at least six months.
We will include trials which include patients with disorders other
than CFS as long as more than 90% of the patients had a primary
CFS diagnosis according to the criteria above. Trials in which less
than 90% of participants had a primary diagnosis of CFS will
only be included in the analysis of this review if data for CFS are
reported separately.
Comorbidities
Studies involving participants with comorbid physical or common
mental disorders are eligible for inclusion, as long as the diagnoses
of CFS is not excluded by the comorbid condition.
Types of interventions
Experimental intervention
Exercise therapy as monotherapy or as an adjunctive treatment
(e.g. exercise combined with pharmacological treatment). We de-
fine exercise therapy as aerobic or anaerobic interventions aimed at
exercising bigmuscle groups, for examplewalking, swimming, jog-
ging, strength or stabilising exercises. Both individual and group
treatment modalities are eligible, but interventions should be
clearly described and supported by appropriate references. We do
not impose restrictions with regard to the duration of each treat-
ment session, number of sessions or time between each session.
Trials presenting data from one of the following comparisons are
eligible for inclusion:
Comparator interventions
1. Standard care - to include passive conditions of treatment as
usual and waiting list, and active conditions of relaxation/
flexibility, pacing and supportive listening.
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2. Psychological therapies - to include cognitive behavioural
therapies, psychodynamic therapies and humanistic/supportive
therapies.
3. Pharmacological treatments - to include antidepressants,
hypnotics, antiviral drugs and immunotherapy.
A non-active supportive listening is regarded as non-active by the
trialists and active by participants, whereas a supportive therapy is
regarded as active by both trialists and participants.
Types of outcome measures
Note: ’Validated’ is defined as having undergone psychometric de-
velopment and having been published in a peer-reviewed journal.
Primary outcomes
Effectiveness
1. Fatigue, measured using a validated scale (e.g. Fatigue Scale (FS)
(Chalder 1993) or the Fatigue Severity Scale (FSS) (Krupp 1989)).
2. Drop out from treatment.
Secondary outcomes
3. Physical functioning, measured using a validated scale (e.g. SF-
36, physical functioning sub scale (Ware 1992)).
Safety
4.Serious adverse reactions and events, measured using any re-
porting system (e.g. Serious Adverse Reactions (SAR) (European
Union Clinical Trials Directive 2001)).
5. Pain, measured using a validated scale (e.g. Visual Analogue
Scale for Pain (VASpain) (Finch 2002)).
6. Mood disorders, measured using a validated scale (e.g. Hospital
Anxiety and Depression Scale (Zigmond 1983)).
7. Sleep duration and quality, measured using a validated scale
(e.g. Pittsburgh Sleep Quality Index (Buysse 1989)).
8. Self-perceived changes in overall health, measured using a vali-
dated scale (e.g. Global Impression Scale (Guy 1976)).
9. Symptom severity, treatment response and efficacy, measured
using a validated scale (e.g. Clinical Global Impression - Severity
scale (CGI-S) (Guy 1976)).
10. Overall functional status, measured using a validated scale (e.g.
Work and Social Adjustment Scale (Mundt 2002)).
11.Objectivemeasures of fitness e.g. VO2maxorVO2 at subjective
maximal effort, measured for example by 100 watts on an exercise
bicycle or running at six miles per hour.
Timing of outcome assessment
Data on each outcome will be extracted for short-term (end of
treatment), medium-term follow up (three to nine months) and
long-term follow up (nine months or more).
Search methods for identification of studies
Electronic searches
The Cochrane Collaboration’s Depression, Anxiety and Neurosis
(CCDAN) Review Group’s Trials Search Coordinator (TSC) will
search their Group’s Specialized Register (CCDANCTR-Studies
and CCDANCTR-References). This register is created from rou-
tine generic searches of MEDLINE (1950- ), EMBASE (1974-
) and PsycINFO (1967- ). Details of CCDAN’s generic search
strategies, used to inform the CCDANCTR can be found on the
Group‘s website.
The CCDANCTR-Studies Register will be searched using the
following terms:
Diagnosis = (“Chronic Fatigue Syndrome” or fatigue) and Free
Text = (exercise or sport* or relaxation or “multi convergent” or
“tai chi”)
The CCDANCTR-References Register will be searched using
a more sensitive list of free-text search terms to identify addi-
tional untagged/uncoded references, e.g. fatigue*, myalgic en-
cephalomyelitis*, exercise, physical active* and taiji. Full search
strategy listed in Appendix 1.
A complementary search of the following bibliographic databases
and international trial registers will also be conducted (see
Appendix 2):
• SPORTSDiscus (1985 to present);
• The Cochrane Central Register of Controlled Trials
(CENTRAL, all years); and
• WHO International Clinical Trials Portal.
Searching other resources
We will contact the authors of included studies, and screen refer-
ence lists to identify additional published or unpublished data.We
will also conduct citation searches using the ISI Science Citation
Index on the Web of Science.
Data collection and analysis
Selection of studies
Two review authors will screen the titles and abstracts obtained
from the searches, independently. Trials that appear to fulfil the
selection criteria will be noted and full-text articles retrieved. Two
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review authors will independently assess the full-text articles for
adherence to the selection criteria. In the case of disagreement, we
will attempt to reach a resolution through discussion. Should this
prove unsuccessful, a third review author or staff at the CCDAN
editorial base will be consulted.
The trialists of the included trials will be invited to take part in
a collaborative group by a letter (Appendix 3) stating the main
aims and purpose, importance of contribution, publication policy
and confidentiality of data. The trialists who provide data will be
offered co-authorship according to the Recommendations for the
Conduct, Reporting, Editing, and Publication of Scholary Work
in Medical Journals (ICMJE 2014). The local secretariat will be
based at the Norwegian Knowledge Centre of the Health Services,
and the first author will act as project manager. The CCDAN
editorial group will act as advisory board. We will ask the trial-
ists to provide their raw data to enable us to assemble the most
complete data set possible, including all randomised participants,
using flexible data formats containing pseudo-anonymised patient
data. The data will be kept and used in accordance with the Nor-
wegian Data Inspectorate’s recommendations, and the parties will
sign a contract (Appendix 4) to this end. An eligible trial will not
be excluded if we cannot obtain access to the raw data.
We will prepare a flow diagram decipiting the flow of references/
studies through the different phases of the review in accordance
with the PRISMA statement (Mother 2009). The flow diagram
will map out the number of records identified, included and ex-
cluded and reasons for exclusion.
Data extraction and management
Trialists of included studies will be invited to collaborate in ac-
cordance with section 18.2 of the Cochrane Handbook (Stewart
2011). They will be offered authorship and asked to provide IPD
for all randomised participants to be used in the review. A list of
variables that we will particularly request is attached (Appendix
5), but we will accept data sets containing more variables than
requested. We will accept all data sent in data formats that can
be read by SAS or SPSS, Microsoft Access databases, Excel and
delimited or (comma-)separated text-files. The review authors will
adopt data security measures to ensure data protection, and to en-
sure that the data cannot be violated or tracked. All data sets will
be stored securely and pseudo-anonymously; that is, all identifiers
that potentially could be linked directly to the actual participants
will be deleted, and identifiers will only be identifiable to the orig-
inal investigators.
Once the raw data is received from the trialists, checks for consis-
tency and comparison with results presented in the journal papers,
will be performed by JO-J. Any queries arising from these checks
will be resolved in cooperation with the trialists. All analyses based
on the Individual Patient Data from the included trials for this
review will be undertaken by JO-J, while meta-analyses will be
performed by JO-J and KGB, independent of trialists. Descriptive
data (methodology, treatment, comparator, and instruments used
for measuring outcomes) for each of the included studies will be
independently extracted by JO-J and LL using a standardised data
collection form (Appendix 6) which will include the following
variables.
Study methodology specific:
• Diagnostic criteria used for identifying eligible patients;
• Method of recruitment for trial;
• Randomisation method;
• Allocation concealment; and
• Blinding.
Treatment specific:
• Deliverer of intervention;
• Explanation and material;
• Type of exercise;
• Schedule, therapist;
• Schedule, home;
• Duration of sessions;
• Initial exercise level;
• Increment steps;
• Patient self monitoring; and
• Criteria for (non) increment.
Outcome specific:
Scales used for assessment
• Fatigue;
• Pain;
• Physical functioning;
• Depression;
• Anxiety; and
• Quality of life.
Measurement time points/follow-up will be collected and study
authors contacted to provide additional information where gaps
have been identified.
For included studies from which we are not able to gain access to
IPD, relevant information (both the above-mentioned data and
results for the prespecified outcomes) will be extracted. For adverse
events, we will extract the number of events and number of partic-
ipants in each group. For the remaining (continuous) outcomes,
we will extract N, mean and standard deviation.
Planned comparisons
1. Exercise therapy versus treatment as usual/waiting list/
supportive listening/pacing/cognitive treatment. We also plan to
conduct subgroup comparisons for each comparison above to see
if one of the more passive comparators is more effective than
another.
2. Exercise therapy (as monotherapy or adjunctive therapy)
versus cognitive behavioural therapy. Monotherapy and
adjunctive therapy will be analysed separately.
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3. Exercise therapy (as monotherapy or adjunctive therapy)
versus pharmacological treatment.
If there are several drug trials we will divide the comparators
into antidepressants, hypnotics, antiviral and immunotherapy.
Monotherapy and adjunctive therapy will be analysed separately.
Data checking and cleaning
To reduce potential bias (Tierney 2005), we will request informa-
tion for all randomised patients including those who had been ex-
cluded from the investigators’ original analyses. A number of stan-
dard checks will be applied to all incoming trials, including checks
for missing values, data validity and consistency across variables.
To assess the randomisation integrity, we will look for unusual
patterns in the sequencing of allocation or imbalances in baseline
characteristics between treatment arms. Follow-up of patients will
be assessed to ensure that it was balanced in the treatment arm,
and as up-to-date as possible.
All incoming data will be checked thoroughly for consistency and
completeness of follow-up. We will tabulate summary measures
(frequencies for categorical variables and mean, standard devia-
tions, minimum, maximum, median, 25th and 75th percentile for
continuous variables) for the individual parameters (demographic
variables, illness-specific variables and outcomes) for each study to
identify missing data and outliers, and to describe differences in
distribution between the studies. We will analyse patient and dis-
ease characteristics and treatment outcome by trial and treatment
arm to check consistency with published results. If we encounter
any problems regarding missing data, obvious errors, discrepan-
cies (e.g. between published data and raw data), inconsistencies
between variables or extreme values or inability to replicate the
results presented in the retrieved papers, we will resolve these in
discussion with the original investigator. We will maintain a log of
all changes made to the data originally supplied by the trialists, and
the reasons for these changes. Any queries will be resolved and the
final database entries verified by the responsible trial investigator
or statistician.
As the summary statistics for outcomes in this review may differ
from the summary statistics presented in the retrieved papers due
to the possible use of imputed data in the original analyses by trial
investigators, we will present summary statistics for all outcomes
by trial and treatment arm in a table (showing sample size, mean,
standard deviation, minimum and maximum).
Assessment of risk of bias in included studies
Two authors (LL and JO-J) will use the Cochrane Collabora-
tion’s tool for assessing risk of bias (Higgins 2011a), published
in the most recent version of the Cochrane Handbook (Higgins
2011b). This tool encourages consideration of how the allocation
sequence was generated, how allocation was concealed, the in-
tegrity of blinding at outcome level, the completeness of outcome
data, selective outcome reporting (only applicable in cases where
we do not gain access to complete data sets) and other potential
sources of bias. When it comes to blinding, we will distinguish be-
tween performance bias (blinding of participants and personnel)
and detection bias (blinding of outcome assessors; for outcomes
not reported/assessed by the participants). As all the outcomes we
intend to look at are subjective (self report by participants, or the
use of scales that are based on judgements) we will include an
item for objective outcomes. Each item in the ’Risk of bias’ assess-
ment will be assessed as low, high or unclear risk of bias using the
guidelines outlined in the Cochrane Handbook (Higgins 2011a).
In addition, we will make an overall assessment of the risk of bias
across all items for each included study. If one or more of the items
sequence generation, allocation concealment or completeness of
outcome data are assessed as being at high risk of bias, the overall
assessment of the study will be high risk of bias.
We will perform sensitivity analyses in which studies assessed to
be at high risk of bias (across all items) are excluded. The reasons
for the judgement ’high risk of bias’ might vary between studies
where IPD are available and studies where IPD are not available.
Selective outcome reporting will only be a problem for non IPD-
studies as we have access to all data from the included studies with
IPD. Furthermore we can reduce the risk of bias due to non-com-
pleteness of outcome data for studies with IPD by using statistical
methods that do not exclude participants based on missing data
(such as analysis of longitudinal data, or the use of censoring when
analysing time-to-event data).
Measures of treatment effect
1. Binary data
We will calculate the odds ratio (OR) and its 95% confidence
interval (CI).
2. Continuous data
When the same scale has been used in all included studies, we
will calculate the mean differences (MD) and their 95% CI, as
it preserves the original units and is therefore easier to interpret.
Where different scales are used for the same outcome, effect sizes
will be calculated separately for each scale.
2.1 Change versus endpoint data
Mean differences will primarily be based on endpoint data. For
studies where IPD are not available, we will only use change data
when endpoint data are not available. In cases where results from
some studies are based on change data and results from other
studies are based on endpoint data, all studies will be included
in the same meta-analysis with change data and endpoint data as
subgroups.
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Unit of analysis issues
Cluster-randomised trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
Where clustering is not accounted for in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We will seek to contact first
authors of studies to obtain the intra-class correlation co-efficient
(ICC) of their clustered data and to adjust for this using accepted
methods (Gulliford 1999). Where clustering is incorporated, we
will present the data as if from a parallel-group randomised study,
but adjusted for the clustering effect. We will additionally exclude
such studies using a sensitivity analysis.
If cluster studies are appropriately analysed taking into account
ICC and relevant data documented in the report, synthesis with
other studies will be possible using the generic inverse variance
technique.
Cross-over trials
A major concern of cross-over trials is the potential for carryover
effect. It occurs if an effect (e.g. pharmacological, physiological or
psychological) of the treatment in the first phase is carried over to
the second phase. As a consequence on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in CFS/ME, randomised
cross-over studies will be eligible for inclusion, but only data up
to the point of first cross-over will be used, while data from the
following (second) period of the cross-over trial will not be con-
sidered for analysis. This might introduce bias due to the possi-
bility of selectively reporting results from the first period based on
the results. We will exclude cross-over studies using a sensitivity
analysis.
Studies with multiple treatment groups
1. Multiple dose groups
We expect that some studies will address the effects of different
levels of supervision and follow-up in regards to the exercise in-
tervention to the comparator (e.g. sessions for designing exercise
therapy, sessions for designing exercise therapy and planned tele-
phone contacts, sessions for designing exercise therapy and seven
face to face treatment sessions, and usual care). In the case of di-
chotomous outcomes we will sum up the sample sizes and the
number of people with events across all intervention groups. For
continuous outcomes, we will combine means and standard devi-
ations using methods described in Chapter 7 (section 7.7.3.8) of
the Cochrane Handbook (Higgins 2011b).
2. Multiple medications
We expect that some other studies will combine several interven-
tions with one comparison group. In this case we will analyse the
effects of each intervention group versus placebo separately, but
will divide up the total number of participants in the placebo
group. In the case of continuous outcomes the total number of
participants in the placebo group will again be divided up, but the
means and standard deviations will be left unchanged (see chapter
16, section 16.5.4 in Higgins 2011b).
Dealing with missing data
Analyses of all endpoints, subsets and subgroups will carried out
on the basis of the intention-to-treat principle but based on the
available data; that is, participants will be analysed according to
their allocated treatment, irrespective of whether they received that
treatment or not, but no attempt will be made to impute missing
data. In our request for the raw data from the included trials it will
be made clear that data are needed for all randomised participants.
Assessment of heterogeneity
We will assess clinical heterogeneity across the included trials in
terms of interventions, participants and settings. We expect that
the trials might differ when it comes to the ingredients of the
active interventions and the components of the passive controls
(treatment as usual, waiting list, etc.). We furthermore anticipate
that the severity and duration of CFS might differ between the
trials. If we judge that the included trials are too heterogeneous
(e.g. we expect the effect sizes across trials to be unrelated) to
warrant a formal meta-analysis, we will not performmeta-analysis
but present the results of the included trials narratively.
We will assess statistical heterogeneity on the basis of the Cochrane
Handbook recommendations (I2 values of 0% to 40%: might not
be important; 30% to 60%: may represent moderate heterogene-
ity; 50% to 90%: may represent substantial heterogeneity; 75%
to 100%: considerable heterogeneity). In addition to the I2 value
(Higgins 2003), we will present the χ2 and its P value and con-
sider the direction and magnitude of the treatment effects. As in
meta-analysis with few studies, the χ2 test is underpowered to
detect heterogeneity should it exist; a P value of 0.10 is used as a
threshold of statistical significance.
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Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These biases
included publication bias and selective outcome reporting bias.
Funnel plots can be useful in reporting biases (Sterne 2011, section
10.4). It is important to bear in mind when interpreting a funnel
plot, that publication and selective outcome reporting biases are
not the only reasons for asymmetry. Poor methodological quality
of studies, inappropriate analysis and true heterogeneity between
trials can also lead to funnel plot asymmetry.
We will only produce funnel plots if at least 10 studies are in-
cluded for that specific outcome and the studies are not similar
in size. Funnel plots will be inspected visually and Egger’s test for
asymmetry (Egger 1997) used to assess the risk of reporting bias.
We will interpret the results with caution; all test results will be as-
sessed in light of the visual inspection. We acknowledge that tests
for funnel plot symmetry in general have relatively low power to
detect funnel plot asymmetry. Thus bias cannot be excluded even
if the test does not provide evidence of funnel plot asymmetry.
For studies where we obtain IPD, we do not consider selective
outcome reporting to be a problem, as we have access to all data
collected. For the remaining non-IPD studies, selective outcome
reporting can be an issue, which will be addressed during the ’Risk
of bias’ assessment.
Data synthesis
Data from the included studies will be analysed using a two-step
approach (Riley 2008).
At the first step, we will analyse the IPD for each trial, separately.
For continuous outcomes the study-level analyses will be based
on repeated measurements with a reference group coding of inde-
pendent factors, thus taking into account the correlation between
baseline and post-intervention measurements. Data from all mea-
surement points will be included in one single model. The post
intervention measurements will be modelled as depending on the
baseline measurement, time. group (intervention or control) and
the interaction between time and group. The repeated measure-
ments (from the same person) will be assumed to have an unstruc-
tured covariance structure. The analyses of data from the individ-
ual included trials will be conducted using the MIXED procedure
in SAS (SAS 2009). For each trial the estimate of effect at any given
measurement point will be calculated as the difference between
the estimated value of the dependent variable in the intervention
and control groups, respectively (at that measurement point); the
corresponding 95% confidence intervals will also be calculated.
If a study has performed more than one measurement of the same
outcome at baseline, the baseline value for our analysis will be
defined as the last value. If measurement of an outcome has been
performed more than once at each measurement point, then we
will base our analysis on the first-measured value.
For studies where no IPD are available, the estimate of effect (MD
with standard error) will be based on the sample sizes, means,
standard deviations, confidence intervals and P values extracted
from papers.
At the second step we will combine the estimates of effect across
studies in meta-analysis. The primary analyses will be based on
all included studies, both IPD and non-IPD, but we will conduct
sensitivity analyses in which studies where IPD are not available
will be excluded. The estimates of effect from all included studies
will be pooled using the generic inverse variance technique in a
random-effects model.
Adverse events will be counted and reported for each study using
odds ratios (ORs) and their 95% confidence intervals. A random-
effects model will be used to estimate effects across studies.
We will use GRADE to examine the quality of evidence and the
strength of recommendations. Judgment of the strength of a rec-
ommendation will require consideration of the following factors:
the balance between benefit and harm, the quality of the evidence,
translation of the evidence into specific circumstances and the cer-
tainty of the baseline risk (Guyatt 2008).
Subgroup analysis and investigation of heterogeneity
To examine the potential impact of trial design and the treatments
used, we plan to group trials by important aspects that might
influence the effect of exercise therapy.
Heterogeneity will be explored on the following trial-specific
items:
• Control groups (treatment as usual/waiting list versus
relaxation/flexibility);
• Diagnostic criteria used for assessing eligibility of
participants (Oxford (Sharpe 1991) versus CDC1994 (Fukuda
1994) versus London ME criteria (The London Criteria 1994)
versus ICC (Carruthers 2011)); and
• Setting (primary versus secondary versus tertiary care).
For each of these analyses a pooled measure of treatment effects
will be calculated for each group of trials and for all trials together.
Participant-specific items:
• Age (less than 45 years of age versus 45 years or older);
• Gender;
• Length of syndrome history (less then 5 years versus more
than 5 years);
• Baseline illness severity (dichotomised);
• Baseline anxiety (Yes/No);
• Baseline depression (Yes/No);
• Comorbidity (Yes/No);
• Diagnostic criteria met (Met least strict criteria versus met
two sets of criteria versus met three sets of criteria versus met all
four sets of criteria); and
• Illness beliefs (virus/psychological/combination).
We will furthermore explore heterogeneity on the following inter-
vention-specific items:
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• Baselining (no determination/patient-centred/
physiological);
• Type of exercise (aerobic/anaerobic-strengthening/
anaerobic-non-strengthening);
• Explanations and materials (no cognitive component/
educational-didactic/educational-didactic plus therapist using
cognitive approaches); and
• Incremental steps (none/pacing/mutually planned and
expected/physiological response to exercise).
For the participant-specific items we will calculate separate esti-
mates of treatment effect for each subgroup using the same meth-
ods as for the main analyses. Pooled measures of treatment effect
will be calculated for each subgroup of the population, but not
across subgroups due to the dependency between estimates of ef-
fect from the same trial.
If enough trials are included (a minimum of 10 studies with all
relevant data available per comparison), meta-regression (random-
effects) will be performed to formally explore heterogeneity or
differences between subgroups of trials or populations. We will
perform one meta-regression for each variable we wish to explore
(not adjusted for the other proposed subgroup variables). The
meta-regression will be conducted using the MIXED procedure
with random error terms for each trial in SAS (SAS 2009). Due
to the number of subgroup analyses we will adjust the level of
significance to 0.05/(#number of subgroup analyses) using the
Bonferroni correction method.
Sensitivity analysis
Sensitivity analysis will be performed, separately, by excluding:
• studies assessed as being at high risk of bias on one or more
of the ’Risk of bias’ items: sequence generation, allocation
concealment or completeness of outcome data;
• cluster-randomised trials;
• cross-over trials (possible selective reporting of results from
first period in non-IPD studies); and
• studies where IPD are not available (estimates of treatment
effect depends on the method of analysis).
We will, in addition, perform sensitivity analyses based on stan-
dardised mean differences (SMD) for continuous outcomes that
have been measured using different instrument/scales in the in-
cluded studies. For the outcome Clinical Global Impression Scale
(CGI) we will perform sensitivity analyses based on dichotomised
values:
• Participant became better (1 and 2 versus 3 to 7); and
• Participant became worse (6 and 7 versus 1 to 5).
’Summary of findings’ tables
Wewill prepare ’Summary of findings’ tables to summarise the key
findings of the systematic review in line with the standard meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011b) using GRADEpro (Brozek 2008).
These findings will include:
• Fatigue;
• Drop out rates;
• Physical functioning; and
• Self-perceived changes in overall health.
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A P P E N D I C E S
Appendix 1. Search strategy - CCDANCTR-References
The Cochrane, Depression, Anxiety and Neurosis Review Group’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintain two clinical trials registers at their editorial base in
Bristol, UK, a references register and a studies based register. The CCDANCTR-References Register contains over 34,000 reports of
randomized controlled trials in depression, anxiety and neurosis. Approximately 60% of these references have been tagged to individual,
coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through
the use of unique Study ID tags. Coding of trials is based on the EU-Psi coding manual. Please contact the CCDAN Trials Search
Coordinator for further details. Reports of trials for inclusion in the Group’s registers are collated from routine (weekly), generic searches
of MEDLINE (1950-), EMBASE (1974-) and PsycINFO (1967-); quarterly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trials
registers c/o the World Health Organisation’s trials portal ( ICTRP), ClinicalTrials.gov, drug companies, the hand-searching of key
journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN’s generic search strategies can be found on the Group‘s website.
There will be no restriction on date, language or publication status applied to the search.
CCDANCTR-Studies and CCDANCTR-References Register will be searched using the following terms:
#1. “chronic fatigue”
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#2. CFS:ti,ab
#3. ((fatigue* or asthenia or “muscular disorder*” or neurasthenia* or “infectious mononucleos*” or “myalgic encephalomyelit*” or
“royal free disease*” or lassitude or “muscular weakness*” or “akureyri disease” or “atypical poliomyelitis” or CFIDS or CFS or (chronic
and mononucleos*) or “epidemic neuromyasthenia” or “iceland disease” or “post infectious encephalomyelitis” or PVFS or tiredness
or adynamia or legasthenia or (perspective and asthenia) or neurataxia or (“muscle strength” and loss) or “muscle* weak*” or “weak*
muscle*” or (muscular and insufficiency) or (neuromuscular and fatigue)) AND (sport* or exercise or “physical fitness” or “physical
education” or “physical condition*” or “physical train*” or “physical mobility” or “physical activ*” or “physical exertion” or “physical
effort*” or ”physical medicine“ or (breathing and (therap* or exercise*)) or (respiration and therap*) or “qi gong” or qigong or qi-
therapy or *kung or tai or thai or taiji or taijiquan or taichi or walking or hiking or yoga or relaxation* or gymnastics or calisthenics or
aerobic or danc* or jumping or hopping or running or jogging or ambulat* or “muscle strengthening” or (muscular and (strength or
resistance)) or ((weight or weights) and lifting) or weightlifting or “power lifting” or “weight train*” or pilates or stretching or plyometric*
or “cardiopulmonary conditioning” or “motion therap*” or “neuromuscular facilitation*” or “movement therap*” or ((recreation or
activity) and therap*) or “isometric training” or climbing or cycling or bicycl* or “lifting effort*” or swim* or aquatic or (training and
(technical or course or program*)) or writing or kinesi* or gardening or multiconvergent))
#4. (#1 or #2 or #3)
#5. cancer
#6. (#4 not #5)
Appendix 2. Other search strategies
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [Exercise] explode all trees
#2 MeSH descriptor: [Exercise Therapy] explode all trees
#3 MeSH descriptor: [Exercise Movement Techniques] explode all trees
#4 MeSH descriptor: [Physical Fitness] this term only
#5 MeSH descriptor: [Physical Education and Training] explode all trees
#6 MeSH descriptor: [Sports] explode all trees
#7 exercis*:ab,kw,ti
#8 ((breathing or respiration) near/2 (therap* or exercis*)):ab,kw,ti
#9 relaxation:ab,kw,ti
#10 (”qi gong“ or qigong or gigong or ”chi gung“ or ”chi gong“ or ”chi kung“):ab,kw,ti
#11 yoga:ab,kw,ti
#12 (”tai chi“ or tai-chi* or taiji or taijiquan or taichi or tai-yi or tai-ji):ab,kw,ti
#13 (physical near/2 (fitness or condition* or education or training or mobility or activit* or exertion or effort)):ab,kw,ti
#14 (gymnastics or calistenics):ab,kw,ti
#15 aerobic*:ab,kw,ti
#16 danc*:ab,kw,ti
#17 (jumping or hopping):ab,kw,ti
#18 (walking or jogging or running):ab,kw,ti
#19 ambulat*:ab,kw,ti
#20 (muscle next strengthening):ab,kw,ti
#21 (muscular near/2 (strength or resistance)):ab,kw,ti
#22 ((weight or weights) near/2 lift*):ab,kw,ti
#23 (weightlifting or power next lifting or weight next training):ab,kw,ti
#24 (Pilates or stretching or plyometric* or cardiopulmonary next conditioning or motion next therap* or neuromuscular next fa?
cilitation* or movement next therap* or gymnastic next therap* or isometric next training or climbing or cycling or lifting next effort*
or swimming or writing):ab,kw,ti
#25 ((recreation or activity) near/2 therap*):ab,kw,ti
#26 ”technical training“:ab,kw,ti
#27 (training near/2 (course* or program*)):ab,kw,ti
#28 kinesi?therap*:ab,kw,ti
#29 gardening:ab,kw,ti
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#30 multiconvergent:ab,kw,ti
#31 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #19 or #21 or #
22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30)
#32 MeSH descriptor: [Fatigue Syndrome, Chronic] this term only
#33 MeSH descriptor: [Asthenia] this term only
#34 MeSH descriptor: [Neurasthenia] this term only
#35 (chronic next fatigue*):ab,kw,ti
#36 (fatigue next syndrom*):ab,kw,ti
#37 (infectious next mononucleos*):ab,kw,ti
#38 (chronic next fatigue-fibromyalgia next syndrome*):ab,kw,ti
#39 (myalgic next encephalomyelit*):ab,kw,ti
#40 (royal next free next disease*):ab,kw,ti
#41 (neurast?enic next neuros*):ab,kw,ti
#42 ((akureyri or iceland*) next disease):ab,kw,ti
#43 ”atypical poliomyelitis“:ab,kw,ti
#44 (CFIDS or CFS):ab,kw,ti
#45 (chronic near/5 mononucleos*):ab,kw,ti
#46 ”epidemic neuromyasthenia“:ab,kw,ti
#47 (post next infectious next encephalomyelit*):ab,kw,ti
#48 PVFS:ab,kw,ti
#49 (perspective near/5 ast?enia):ab,kw,ti
#50 (neurast?enic next syndrome*):ab,kw,ti
#51 neurataxia:ab,kw,ti
#52 neurast?enia:ab,kw,ti
#53 (neuromus?ular near/6 fatigue):ab,kw,ti
#54 (#32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49
or #50 or #51 or #52 or #53)
#55 #31 and #54 [in Trials]
SPORTSDiscus (EBSCOHost)
S67 (S38 AND S61 AND S66)
S66 (S62 OR S63 OR S64 OR S65)
S65 TI (((singl* or doubl* or tripl*) W0 (blind* or mask* or dummy)) ) OR AB ( ((singl* or doubl* or tripl*) W0 (blind* or mask* or
dummy)))
S64 TI ((control* or prospectiv* or volunteer*)) OR AB ((control* or prospectiv* or volunteer*))
S63 TI ((clinic* N2 (trial? or study or studies))) OR AB ((clinic* N2 (trial? or study or studies)))
S62 TI ((randomi?ed or randomly or placebo? or trial?) ) OR AB ( (randomi?ed or randomly or placebo? or trial?))
S61 (S39 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54
OR S55 OR S56 OR S57 OR S58 OR S59 OR S60)
S60 TI (neuromuscular N5 fatigue) OR AB (neuromuscular N5 fatigue)
S59 TI neuroasthenia OR AB neuroasthenia
S58 TI neurataxia OR AB neurataxia
S57 TI (neurasthenic W0 syndrome*) OR AB (neurasthenic W0 syndrome*)
S56 TI (perspective N3 asthenia) OR AB (perspective N3 asthenia)
S55 TI PVFS OR AB PVFS
S54 TI post-infectious W0 encephalomyelitis OR AB post-infectious W0 encephalomyelitis
S53 TI epidemic W0 neuromyasthenia OR AB epidemic W0 neuromyasthenia
S52 TI (chronic N4 mononucleos*) OR AB (chronic N4 mononucleos*)
S51 TI ((CFIDS or CFS) ) OR AB ( (CFIDS or CFS))
S50 TI atypical W0 poliomyelitis OR AB atypical W0 poliomyelitis
S49 TI ((akureyri or iceland) W0 disease) OR AB ((akureyri or iceland) W0 disease)
S48 TI neurasthenic W0 neuros* OR AB neurasthenic W0 neuros*
S47 TI royal W0 free W0 disease* OR AB royal W0 free W0 disease*
S46 TI myalgic W0 encephalomyelit* OR AB myalgic W0 encephalomyelit*
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S45 TI chronic W0 fatigue-fibromyalgia W0 syndrome* OR AB chronic W0 fatigue-fibromyalgia W0 syndrome*
S44 TI infectious W0 mononucleos* OR AB infectious W0 mononucleos*
S43 TI fatigue W0 syndrom* OR AB fatigue W0 syndrom*
S42 TI chronic W0 fatigue* OR AB chronic W0 fatigue*
S41 SU Asthenia OR SU Neurasthenia
S39 SU Fatigue Syndrome, Chronic
S38 (S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31
OR S32 OR S33 OR S34 OR S35 OR S36 OR S37)
S37 TI multiconvergent OR AB multiconvergent
S36 TI gardening OR AB gardening
S35 TI kinesi?therap* OR AB kinesi?therap*
S34 TI ((training W0 (course* or program*)) ) OR AB ( (training W0 (course* or program*)))
S33 TI technical W0 training OR AB technical W0 training
S32 TI writing OR AB writing
S31 TI lifting W0 effort* OR AB lifting W0 effort*
S30 TI (climbing or cycling or swimming) OR AB (climbing or cycling or swimming)
S29 TI isometric W0 training OR AB isometric W0 training
S28 TI gymnastic W0 therap* OR AB gymnastic W0 therap*
S27 TI (((recreation or activity) W0 therap*)) OR AB (((recreation or activity) W0 therap*))
S26 TI neuromuscular W0 fa?cilitation* OR AB neuromuscular W0 fa?cilitation*
S25 TI (((motion or movement) W0 therap*)) OR AB (((motion or movement) W0 therap*))
S24 TI cardiopulmonary W0 conditioning OR AB cardiopulmonary W0 conditioning
S23 TI plyometric* OR AB plyometric*
S22 TI stretching OR AB stretching
S21 TI pilates OR AB pilates
S20TI (((weight?N1 lifting) or weightlifting or powerW0 lifting or weightW0 training) )ORAB ( ((weight?N1 lifting) or weightlifting
or power W0 lifting or weight W0 training))
S19 TI (((muscular or muscle) W0 (strength or resistance) W0 training)) OR AB (((muscular or muscle) W0 (strength or resistance)
W0 training))
S18 TI muscle W0 strengthening OR AB muscle W0 strengthening
S17 TI ambulat* OR AB ambulat*
S16 TI ((jumping or hopping or jogging or running) ) OR AB ( (jumping or hopping or jogging or running))
S15 TI (aerobic W0 danc* or danc*) OR AB (aerobic W0 danc* or danc*)
S14 TI (gymnastics or calisthenics) OR AB (gymnastics or calisthenics)
S13 TI ((physical W0 (fitness or condition* or education or training or mobility or activit* or exertion or effort))) OR AB ( (physical
W0 (fitness or condition* or education or training or mobility or activit* or exertion or effort)))
S12 TI yoga OR AB yoga
S11 TI walking OR AB walking
S10 TI (”tai-chi*“ or taiji or taijiquan or taichi or ”tai-yi“ or ”tai-ji“) OR AB (”tai-chi*“ or taiji or taijiquan or taichi or ”tai-yi“ or ”tai-
ji“)
S9 TI (”qi gong“ or qigong or gigong or ”chi gung“ or ”chi gong“ or ”chi kung“) OR AB (”qi gong“ or qigong or gigong or ”chi gung“
or ”chi gong“ or ”chi kung“)
S8 TI relaxation* OR AB relaxation*
S7 TI (((breathing or respiration) W0 (therap* or exercise*)) ) OR AB ( ((breathing or respiration) W0 (therap* or exercise*)))
S6 TI ((exercise* or exercising)) OR AB ((exercise* or exercising))
S5 SU ”physical education & training“+
S4 SU physical fitness
S3 SU ”exercise therapy“+
S2 SU exercise+
S1 SU sports+
International Trial Registers
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WHO International Clinical Trials Portal available at: http://apps.who.int/trialsearch/, incorporating the following International trials
registers/registries:
• Australian New Zealand Clinical Trials Registry
• ClinicalTrials.gov
• EU Clinical Trials Register (EU-CTR)
• ISRCTN
• Brazilian Clinical Trials Registry (ReBec)
• Chinese Clinical Trial Registry
• Clinical Trials Registry - India
• Clinical Research Information Service - Republic of Korea
• Cuban Public Registry of Clinical Trials
• German Clinical Trials Register
• Iranian Registry of Clinical Trials
• Japan Primary Registries Network
• Pan African Clinical Trial Registry
• Sri Lanka Clinical Trials Registry
• The Netherlands National Trial Register
• Thai Clinical Trials Register (TCTR)
Appendix 3. Letter of invitation
Dear Dr XXX,
Following up our previous communication on the need to follow up and elaborate on the the Cochrane review ’Chronic Fatigue
Syndrome and graded exercise therapy’ from 2004; your study, XXXX, is one of the studies to be included.
As previously mentioned we intend to conduct an Individual Participant Data (IPD) review. The reason for the IPD review is to
enable in-depth analyses by performing subgroup analyses. This will be carried out using variables such as patient, illness and treatment
characteristics. We are able to handle data delivered in the following formats:
• Excel
• SAS
• SPSS/PASW Statistics
• Delimited or fixed-width files provided that a detailed file-description with variable-names, formats and maximum width of each
column is provided.
Please don’t hesitate to contact us if you need more information. Enclosed is a memorandum which should be returned to us with the
datafiles.
We would like to invite you to participate as co-author(s) in line with your contribution. Should you not wish to be listed as a co-
author you will of course be mentioned under Acknowledgments for the provision of your raw data.
The review will be undertaken in collaboration with representatives from Uni Health Bergen and The Norwegian Knowledge Centre
for the Health Services, Oslo, as well as the authors of the included studies.
Yours sincerely
Lillebeth Larun
Attachments
• Memorandum to be signed
• List of background variables
• Data extraction template
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Appendix 4. Memorandum
Exercise therapy for chronic fatigue syndrome (individual patient data)
Whereas:
The parties have agreed to provide information which they consider to be confidential in nature (the “Confidential Information”) to
write the review: ’Exercise Therapy for Chronic Fatigue Syndrome (Individual Patient Data)’, hereafter called the “Purpose”;
It is agreed as follows:
1. In consideration of each of the parties disclosing to the other Confidential Information for the Purpose the parties hereby
undertake that they shall:
i) not communicate, disclose or make available all or any of the part of the Confidential Information to any third party
ii) not directly or indirectly use, or permit others to use, the Confidential Information other than for the Purpose;
iii) not make any announcements or disclosure in connection with the Confidential Information or the Purpose without prior consent
of the other party.
2. The obligation of the confidentiality and non-use will not apply to any of the following:
i) information which is generally available to the public at the date of this agreement;
ii) information which is subsequently disclosed by third parties having no obligation of confidentiality;
iii) information which is or will become generally available to the public in printed publications in general circulation through no act
or default on the parties.
3. Without prejudice to the generality of clause 2 information shall not be deemed to be generally available to the public by reason
only that it is known to only a few of those people to whom it may be of commercial interest and a combination of two or more parts
of the Confidential Information shall not be deemed to be generally available to the public by reason only of separate part being so
available.
4. The parties shall each ensure that all measures necessary are taken to secure the confidentiality of the other party‘s Confidential
Information including but not limited to:
i) keeping separate all Confidential Information and all information generated based on the Confidential Information from all other
documents and records;
ii) keeping all documents and any other material bearing or incorporating any of the Confidential Information at the party‘s usual
place of business;
iii) not using, reproducing, transforming or storing any of the V in an external accessible computer or electronic information retrieval
system, not transmitting it in any form or by any means outside the party‘s usual place of business and not copying all or any part of
the Confidential Information without the prior consent and then only to the extent that the same is required for the Purpose;
iv) allowing access to the Confidential Information only to those employees and/or to the professional advisers who have reasonable
need to see or use it for the Purpose and informing each of the said employees and professional advisers of the confidential nature
of the Confidential Information and of the obligations in respect of the Confidential Information and ensuring such employees and
professional advisers comply with the confidentiality and non-disclosure obligations in this agreement;
v) obtaining form employees having access to the Confidential Information their undertakings to maintain the same as confidential
and taking such steps as may be reasonable to enforce such obligations;
vi) delivering all documents and other materials in the possessions, custody or control of the party, employees or professional advisers
that bear or incorporate any part of the Confidential Information of the other party;
vii) delivering all data material encrypted wherever possible and make sure that individual participants cannot be identified form the
data provided.
5. The failure by any party to enforce at any time any one or more of the terms or conditions of this agreement shall not be a waiver
of them or of the right at any time subsequently to enforce all terms and conditions in this agreement.
6. The parties agree that damages might not be sufficient remedy to any breach of the terms of this agreement and that as a result
injunctive or other equitable relief may be obtained in respect of any breach or anticipated breach.
7. All right in the Confidential Information are reserved by the party to which it belongs and no rights or obligations other than
those expressly set out in this agreement are granted or to be implied form this agreement. In particular no license is granted directly or
indirectly by this agreement relating to any intervention, discovery, patent, copyright or other industrial or intellectual property right
now or in future held, made, obtained or licensable by either party.
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8. The rights, duties and obligations of the parties and the validity, interpretation, performance and legal effect of this agreement
shall be governed and determined by the laws of country of residence.
AGEED by the parties:
SIGNED by
Name (print)
Position
Date (Day/Month/Year)
SIGNED by
Name (print)
Position
Date (Day/Month/Year)
Appendix 5. List of variables requested from original investigators
Gender (M/F)
Age (years)
Education
Martial status
Income
Employment status
Complied with protocol (Y/N)
Completed follow-up (Y/N)
Number of sessions attended
Duration of illness (years)
Illness severity
Previous diagnosis (specify)
Co-morbidity (specify)
previous treatment
Adjunctive treatment
Illness perception
Medication
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(Continued)
Physical fatigue
Mental fatigue (all measurements)
Total fatigue (all measurements)
Percieved exertion (all measurements)
Depression (all measurements)
Anxiety (all measurements)
Pain (all measurements)
Functional impairment (all measurements)
Quality of life (all measurements)
Adverse outcomes (specify)
Appendix 6. Data collection form - descriptive data
Study specific
Diagnostic criteria for identify-
ing eligible patients
Methods of recruitment for trial
Randomisation method
Allocation concealment
Blinding (who was blinded to
what)
Treatment specific
Deliverer of intervention
Explanation and material
Type of exercise
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(Continued)
Schedule, therapist
Schedule, home
Duration of sessions
Initial exercise level
Increment steps
Patient self monitoring
Criteria for (non) increment
Scales used for assessment Name Self-reported or clinician-reported (please
state bywhom andwhether the clinicianwas
blinded to treatment allocation)
When measured
Fatigue
Pain
Functional impairment
Depression
Anxiety
Quality of life
F E E D B A C K
Exercise therapy for chronic fatigue syndrome (individual patient data), 20 March 2018
Summary
In October 2016 a FOI request was submitted to Queen Mary University London QMUL for additional data from the PACE
trial which was an included study in the previous Cochrane Review on Exercise for CFS. ( http://www.cochrane.org/CD003200/
DEPRESSN exercise-treatment-patients-chronic-fatigue-syndrome). The PI of the PACE trial is now a co-author on this IPD review.
The freedom of information request was rejected in November 2016 citing an exemption in the law that covers data which is part of
ongoing research or scheduled to be included in future publications. Does this refer to the future publication of this review and the
previous review update?
An internal appeal to QMUL was rejected, and the complainant appealed to the Information Commissioners Office (ICO) in March
2017. In the interim, the PI of the PACE trial retired from QMUL.
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During this time, QMUL changed its rationale for not providing the data saying that they were not available because the PI had gone
and they are not required to hire staff to access data in response to FOI requests.
The PI of the PACE Trial is both an author of the Cochrane review and the PI of the PACE trial. So he should be able to provide all
the data needed for the new review. However, QMUL told the ICO that they are the holder and owner of the raw data and have lost
the means to locate and extract it because that requires specialist knowledge. I would argue that the patients that gave their time and
bodies to participate in the trial, and the people who paid taxes to fund the research are the owners of the data, and to deny access to
them is unethical.
Does this mean the Cochrane reviewers will also be unable to access all the raw data from the PACE trial despite the PI being on the
author team?
Submitter name: Caroline Struthers
Role: Patient advocate
Reply
Your comment includes two specific questions in relation to availability of data from the PACE trial.
Your first question relates to the correspondence between QMUL and ICO, in which QMUL has cited an exemption in the law, which
covers data in ongoing research or future publications. The authors of the Cochrane review have, however, not been involved in the
correspondence between QMUL and ICO, and we have no knowledge of what QMUL has referred to in their response.
Your second question relates to the data availability for the Cochrane reviewers in relation to the data from the PACE trial. We can
confirm that theCochrane reviewers will have access to sufficient PACE trial data to perform the review in accordance with theCochrane
protocol (with it’s appendices).
In addition, your comment contains certain statements relating to the FOI request submitted to QMUL, and their responses on the
current availability of raw data from the PACE trial. The Cochrane reviewers have no knowledge of these matters, and can neither
confirm nor reject the statements made in your comment. If someone submits a request for data related to this Cochrane review, it
should however be noted, that the reviewers have a duty of confidentiality on terms equal to those outlined in Appendix 4 in the
protocol.
Contributors
Response from Lillebeth Larun (first author)
WH A T ’ S N E W
Date Event Description
10 May 2018 Feedback has been incorporated Feedback comment and response added.
H I S T O R Y
Protocol first published: Issue 4, 2014
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Date Event Description
20 May 2014 Amended Following questions around the involvement of trialists in the analysis, the protocol has been updated
to clarify how independence will be ensured. Minor amendments were also made to the search strategy
C O N T R I B U T I O N S O F A U T H O R S
Lillebeth Larun (LL), Jan Odgaard-Jensen (JO-J) and Kjetil Gundro Brurberg (KGB) developed and drafted the protocol.
Hugh McGuire and Sarah Dawson, CCDAN Trials Search Coordinators, developed the search with input from LL.
JO-J developed and drafted the statistical analysis.
All the co-authors have contributed to the final draft of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
All analyses for this review will be undertaken by JO-J and KGB independently of trialists providing data.
KGB: none known.
TC: may contribute anonymised individual patient data from one or more trials, and has received royalties from Sheldon Press and
Constable and Robinson for self help books related to chronic fatigue.
MD: none known; may contribute anonymised individual patient data from one or more trials.
PG is on the board of Therapeutic Guidelines Limited, and holds a research grant from the NHMRC on screening and diagnostic
testing.
LL: none known.
REM-M: may contribute anonymised individual patient data from one or more trials, and is a national adviser to NHS England for
Increasing Access to Psychological Therapies for People with Long Term and Medically Unexplained Conditions.
JO-J: none known.
MS: may contribute anonymised individual patient data from one or more trials, and has done occasional consultancy for Aegon
Insurance Ltd.
KW: none known; may contribute anonymised individual patient data from one or more trials.
AW: none known; may contribute anonymised individual patient data from one or more trials.
PDW: may contribute anonymised individual patient data from one or more trials, and has undertaken both voluntary and paid
consultancy work for the UK government and a re-insurance company
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S O U R C E S O F S U P P O R T
Internal sources
• Norwegian Knowledge Centre for the Health Services, Norway.
Wages for JO-J, KGB and LL
External sources
• No sources of support supplied
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